Could a simple calcium injection prevent dangerous bleeding in C-Sections?
NCT ID NCT07550413
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tests whether giving intravenous calcium right after the baby is delivered can reduce blood loss during cesarean sections. About 182 women having a planned or in-labor C-section will receive either calcium plus standard oxytocin or oxytocin alone. The goal is to see if calcium helps prevent postpartum hemorrhage, a leading cause of maternal death.
What this could mean
Our plain-language read of the trial. This is informational only, not medical advice or a prediction.
- Active substance
- calcium chloride
- What this could lead to
- If it works, this could offer a simple, low-cost way to reduce dangerous bleeding during cesarean sections.
- What could go wrong
- This is an early phase 2 trial with only 182 participants, so results may not apply to all women. Calcium can cause heart rhythm issues, especially in those with heart disease.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Phase
-
Phase 2
Tests whether the treatment actually works, and watches for side effects, in a larger group.
- Participants
-
About 182 people
The number the study aims to enrol. It can still change while the study runs.
- Expected to start
-
May 2026
An estimate. Start dates often move.
- Expected to finish
-
Dec 2026
An estimate. End dates often move.
- Lead sponsor
-
Other sponsor
The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
- Ages
-
18 to 45 years
- Sex
-
Female participants only
- Healthy volunteers
-
Accepted
You do not need to have the condition being studied to take part.
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
Inclusion Criteria: * Women aged 18-45 years undergoing intrapartum cesarean section at ≥34 weeks of gestation. * Exposure to oxytocin during labor before CS. * Singleton pregnancy with no known fetal anomalies. Exclusion Criteria: * Known bleeding disorders or preoperative coagulation abnormalities * Preeclampsia or hypertensive disorders contraindicate calcium use. * History of cardiac disease or arrhythmias * Placental abnormalities, i.e., placenta previa, accreta * Emergency CS with fetal distress or cord prolapse. * Known hypersensitivity to calcium chloride.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for Cesarean section surgery are added.
Genom att skicka in godkänner du våra Användarvillkor
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
How to take part
Only the study team decides who joins. These are the ways to reach them.
-
The places running it
1 site. The list below names each one and where it is.
-
The official record
ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.
-
A doctor treating you
A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.
Contacts and locations
Locations
-
Pak Emirates Military Hospital
Rawalpindi, Punjab Province, 44000, Pakistan
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Could a pill replace daily shots for clot prevention after C-Section?
- Wearable patch could warn of deadly Post-Birth bleeding an hour before it happens
- Costly drug may save money in severe childbirth bleeding, but study cut short
- Can a simple drug prevent dangerous bleeding in C-Sections?
- C-section timing may impact newborn health, study finds